MARKET

ENTA

ENTA

Enanta Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

51.69
+0.59
+1.15%
Opening 11:02 04/21 EDT
OPEN
51.23
PREV CLOSE
51.10
HIGH
51.84
LOW
50.70
VOLUME
12.41K
TURNOVER
--
52 WEEK HIGH
58.59
52 WEEK LOW
40.32
MARKET CAP
1.04B
P/E (TTM)
-17.8827
1D
5D
1M
3M
1Y
5Y
Global Primary Biliary Cirrhosis Drug Market Insights, Overview, Analysis and Forecast 2021-2026
Apr 20, 2021 (Heraldkeepers) -- The Primary Biliary Cirrhosis Drug market report provides a detailed analysis of global market size, regional and...
Heraldkeepers · 1d ago
Entera Appoints Ramesh Ratan as Chief Financial Officer
Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of veteran finance and operations executive Ramesh Ratan as U.S. Chief Financial Officer. Mr. Ratan replaces Jonath...
GlobeNewswire · 6d ago
Antibiotics Drugs Market Share 2021 | CAGR Status, Development Trends, Industry Size, Key Manufacturers, Competitive Analysis with Covid-19 Impact till 2027
Apr 15, 2021 (The Expresswire) -- “Final Report will add the analysis of the impact of COVID-19 on this industry” Global “Antibiotics Drugs Market” report...
The Express Wire · 6d ago
RBC Capital Keeps Their Hold Rating on Enanta Pharmaceuticals (ENTA)
RBC Capital analyst Brian Abrahams maintained a Hold rating on Enanta Pharmaceuticals (ENTA) on April 8 and set a price target of $52.00. The company's
SmarterAnalyst · 04/12 01:46
Drugs for Vancomycin-Resistant Enterococcus Faecium Market 2021 Segmentation, Statistics, Top Manufacturers, Regional Analysis and Forecast to 2027
Market Stats News · 04/08 18:37
Global Primary Biliary Cirrhosis Drug Market 2021-2027 with Top Countries Data Industry Size, Share, Business Growth, Revenue, Trends, Market Demand Penetration and Forecast | With Covid-19 Analysis
The Express Wire · 04/05 05:03
Thursday's ETF with Unusual Volume: XSLV
Mar 25, 2021 (MarketNewsVideo.com via COMTEX) -- The Invesco S&P SmallCap Low Volatility ETF is seeing unusually high volume in afternoon trading Thursday,...
MarketNewsVideo.com · 03/25 17:59
Primary Biliary Cirrhosis Drug Market Type , Application and Region - Global Trends and Forecast to 2027 By Ameco Research
pune, India, Thu, 25 Mar 2021 01:40:00 / Comserve Inc. / -- The global Primary Biliary Cirrhosis Drug market is segmented by company, region (country), by...
Comserve · 03/25 05:42
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ENTA. Analyze the recent business situations of Enanta Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ENTA stock price target is 68.14 with a high estimate of 107.00 and a low estimate of 35.00.
EPS
Institutional Holdings
Institutions: 242
Institutional Holdings: 19.92M
% Owned: 98.75%
Shares Outstanding: 20.17M
TypeInstitutionsShares
Increased
56
1.91M
New
10
86.83K
Decreased
60
1.18M
Sold Out
29
436.21K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.45%
Pharmaceuticals & Medical Research
+0.92%
Key Executives
Non-Executive Chairman/Independent Director
Bruce Carter
President/Chief Executive Officer/Director
Jay Luly
Chief Financial Officer/Senior Vice President - Finance
Paul Mellett
Senior Vice President/Chief Scientific Officer
Yat Sun Or
Senior Vice President/General Counsel
Nathaniel Gardiner
Senior Vice President
Nathalie Adda
Senior Vice President
Tara Kieffer
Senior Vice President
Brendan Luu
Independent Director
Mark Foletta
Independent Director
Kristine Peterson
Independent Director
Lesley Russell
Independent Director
Terry Vance
No Data
About ENTA
Enanta Pharmaceuticals, Inc. is a biotechnology company. The Company uses chemistry-driven approach and drug discovery capabilities. The Company is focused on discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The Company has clinical candidates for the disease targets, including respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). It also conducts research in human metapneumovirus (hMPV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or coronavirus disease-2019 (COVID-19). The Company has discovered glecaprevir, a protease inhibitor discovered and developed through its collaboration with AbbVie for the treatment of chronic hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie’s direct-acting antiviral (DAA), a combination treatment for HCV infection under the tradenames: MAVYRET and MAVIRET.

Webull offers kinds of Enanta Pharmaceuticals Inc stock information, including NASDAQ:ENTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENTA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ENTA stock methods without spending real money on the virtual paper trading platform.